|Chemical and physical data|
|Molar mass||477.528 g·mol−1|
|3D model (JSmol)|
NGD-4715 is a drug developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1. In animal models it has anxiolytic, antidepressant, and anorectic effects, and it has successfully passed Phase I clinical trials in humans.
The structure of NGD-4715 has been confused. For example, as 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|